Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ RealReal gains on report of takeover speculation (SeekingAlpha) +++ REALREAL Aktie +3,11%

TANDEM DIABETES Aktie

 >TANDEM DIABETES Aktienkurs 
18 EUR    +13.2%    (TradegateBSX)
Ask: 18.3 EUR / 407 Stück
Bid: 18.1 EUR / 416 Stück
Tagesumsatz: 20 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>TANDEM DIABETES Performance
1 Woche: +20,8%
1 Monat: +25,0%
3 Monate: -10,9%
6 Monate: +51,3%
1 Jahr: +19,1%
laufendes Jahr: -4,4%
>TANDEM DIABETES Aktie
Name:  TANDEM DIABETES NEW -,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US8753722037 / A2H5BX
Symbol/ Ticker:  TD5A (Frankfurt) / TNDM (NASDAQ)
Kürzel:  FRA:TD5A, ETR:TD5A, TD5A:GR, NASDAQ:TNDM
Index:  -
Profil:  Tandem Diabetes Care, Inc. is a medical device company focused on diabetes management technology. Tandem Diabetes Care develops and commercializes automated insulin delivery systems designed for people living with insulin-dependent diabetes, with its..
>Volltext..
Marktkapitalisierung:  1177.2 Mio. EUR
Unternehmenswert:  1437.84 Mio. EUR
Umsatz:  968.89 Mio. EUR
EBITDA:  -7.57 Mio. EUR
Nettogewinn:  -44.38 Mio. EUR
Gewinn je Aktie:  -0.64 EUR
Schulden:  663.98 Mio. EUR
Liquide Mittel:  65.66 Mio. EUR
Operativer Cashflow:  -13.17 Mio. EUR
Bargeldquote:  1.73
Umsatzwachstum:  10.56%
Gewinnwachstum:  74.92%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 29.536 Euro.
Suchwörter:  TANDEM DIABETES
Letzte Datenerhebung:  14.11.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 69.79 Mio. St.
Frei handelbar: 98.76%
Rückkaufquote: -0.2%
Mitarbeiter: 2500
Umsatz/Mitarb.: 0.37 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 58.54%
Bewertung:
KGV: -
KGV lG: -
KUV: 1.09
KBV: 9.01
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 56.6%
Gewinnmarge: -4.58%
Operative Marge: -2.45%
Managementeffizenz:
Gesamtkaprendite: -4.84%
Eigenkaprendite: -36.74%
>Peer Group
Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege, Stoffwechselerkrankungen (Diabetes/ Adipositas)
 
13.11.26 - 16:03
Tandem Diabetes Care jumps 12% on FDA clearance for tubeless Mobi (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.11.26 - 15:54
FDA-Zulassung für schlauchlose Insulinpumpe: Aktie von Tandem Diabetes Care schießt nach oben (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
13.11.26 - 15:48
Tandem Diabetes-Aktie steigt nach FDA-Zulassung für schlauchlose Pumpe um 8 % (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
13.11.26 - 15:45
Tandem Diabetes stock jumps 8% on FDA clearance for tubeless pump (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
06.11.26 - 03:00
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
 
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....
06.11.26 - 01:01
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
 
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +62.96% and +6.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?...
05.11.26 - 22:30
Tandem Diabetes Care GAAP EPS of -$0.10 beats by $0.15, revenue of $283.7M beats by $17.85M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.11.26 - 22:18
Tandem Diabetes Care appoints Jeannette Bankes as CEO (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.11.26 - 22:12
Tandem Diabetes Care Names Jeannette Bankes as President and Chief Executive Officer (Business Wire)
 
Planned Leadership Transition as John Sheridan Retires Following More Than a Decade of ServiceSAN DIEGO--(BUSINESS WIRE)--$TNDM #diabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (“Tandem” or the “Company”), a global diabetes technology company, today announced the appointment of Jeannette Bankes as president and chief executive officer (“CEO”), and a member of its Board of Directors, effective November 16, 2026. Ms. Bankes will succeed John Sheridan, who will retire at the end of 2026 after more than a decade of service to Tandem, as part of a planned leadership transition. Mr. Sheridan has served as Tandem's president and CEO since 2019, after joining the Company as chief operating officer in 2013. During his tenure, Tandem launched a portfolio of automated insulin delivery solutions, while strengthening the organization's ability to operate on a global scale, and has initiated business model changes to simplify and improve technology access. Mr. Sheridan will remain with the Company as ...
04.11.26 - 23:36
Tandem Diabetes Care Q3 2026 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.10.26 - 22:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Tandem Diabetes Care im Wert von 32555 USD (Insiderkauf)
 
Twomey, Christopher J. - Aufsichtsrat - Tag der Transaktion: 2026-10-27...
09.10.26 - 17:30
Is it the Right Time to Hold TNDM Stock in Your Portfolio? (Zacks)
 
Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth....
01.10.26 - 22:12
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026 (Business Wire)
 
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2026 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI99b384cce5da4b33b55d2905f84b8b26) and you will be provided with dial-in details, including a personal pin. An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the “Ev...
17.09.26 - 13:00
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock? (Zacks)
 
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term....
09.09.26 - 22:00
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now (Zacks)
 
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain....
31.08.26 - 19:00
Aging Population Drives Healthcare Growth: Stocks to Watch (Zacks)
 
AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care....
14.08.26 - 03:24
Tandem Diabetes (TNDM) Q2 2026 Earnings Call Transcript (Fool)
 
Pump shipments surged 10% as pharmacy adoption accelerated....
12.08.26 - 16:00
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up (Zacks)
 
Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss....
11.08.26 - 20:36
Tandem Diabetes: Breiterer Marktzugang und neue Produkte sollen Wachstum treiben (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
07.08.26 - 02:30
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
 
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +8.82% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Steter Tropfen höhlt den Stein. - Ovid
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!